Circumventing Pediatric Solid Tumor Microenvironment Resistance by Combinatorial CAR NK and Immunomodulating Therapy |
New York Medical College / Mitchell Cairo, MD |
Reach Grants |
2023 |
New York |
Development of a Novel Mer Tyrosine Kinase Inhibitor for Treatment of ALL |
University of Colorado Denver / Doug Graham, MD, PhD |
Reach Grants |
2013 |
Colorado |
Feasibility Study of Dual Inhibition of MDM2 and Tubulin in Treatment of AML |
Emory University / Muxiang Zhou, MD |
Reach Grants |
2023 |
Georgia |
Novel Strategy for Reducing Radiation-Induced Morbidity and Treating Recurrent Medulloblasoma |
Massachusetts General Hospital / Rakesh Jain, PhD |
Reach Grants |
2013 |
Massachusetts |
Therapeutic Targeting of PGBD5-induced DNA Repair Dependency in Pediatric Solid Tumors |
Memorial Sloan-Kettering Cancer Center / Alex Kentsis, MD/PhD |
Reach Grants |
2017 |
New York |
Immuno-therapeutic Targeting of CD56 in CBA2T3/GLIS2-AML in Children |
Fred Hutchinson Cancer Research Center / Soheil Meshinchi, MD/PhD |
Reach Grants |
2018 |
Washington |
Novel Therapy for Pediatric Leukemia Patients with NUP98 Translocations |
The Regents of the University of Michigan / Jolanta Grembecka, PhD |
Reach Grants |
2022 |
Michigan |
Preclinical Development of a First-in-Class PCNA Inhibitor for Treating Neuroblastoma |
City of Hope National Medical Center / Linda Malkas, PhD |
Reach Grants |
2019 |
California |
Optimization of Drug Efflux and Brain Clearance to Improve CED of Targeted Therapy to H3K27M DMG |
Mayo Clinic / David Daniels, MD/PhD |
Reach Grants |
2021 |
Minnesota |
Generation of CMV-specific CD19 CAR T cells Using Cytokine Capture Followed by Lentiviral Transduction and Expansion |
Research Institute at Nationwide Children's Hospital / Margaret Lamb, MD |
Reach Grants |
2019 |
Ohio |